Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Tadalafil (Primary) ; Tamsulosin
- Indications Benign prostatic hyperplasia; Erectile dysfunction; Lower urinary tract symptoms
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 19 Apr 2016 Results of a pooled analysis from four trials (n= 1462) published in the Journal of Urology
- 24 Aug 2015 Results of post-hoc analysis of pooled data from four trials published in the International Journal of Clinical Practice.
- 15 Apr 2014 Results reporting treatment satisfaction scores presented at the 29th Congress of the European Association of Urology.